EP1475086A3 - Sibutramine metabolites - Google Patents

Sibutramine metabolites Download PDF

Info

Publication number
EP1475086A3
EP1475086A3 EP04018454A EP04018454A EP1475086A3 EP 1475086 A3 EP1475086 A3 EP 1475086A3 EP 04018454 A EP04018454 A EP 04018454A EP 04018454 A EP04018454 A EP 04018454A EP 1475086 A3 EP1475086 A3 EP 1475086A3
Authority
EP
European Patent Office
Prior art keywords
disorders
disorder
desmethylsibutramine
didesmethylsibutramine
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04018454A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1475086A2 (en
Inventor
Thomas P. Jerussi
Chrisantha H. Senanayake
Qun K. Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP1475086A2 publication Critical patent/EP1475086A2/en
Publication of EP1475086A3 publication Critical patent/EP1475086A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Information Transfer Systems (AREA)
EP04018454A 1998-08-24 1999-08-23 Sibutramine metabolites Withdrawn EP1475086A3 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US372158 1982-04-26
US9766598P 1998-08-24 1998-08-24
US97665P 1998-08-24
US9930698P 1998-09-02 1998-09-02
US99306P 1998-09-02
US09/372,158 US6331571B1 (en) 1998-08-24 1999-08-11 Methods of treating and preventing attention deficit disorders
EP99945137A EP1107746B1 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP99945137.0 Division 1999-08-23
EP99945137A Division EP1107746B1 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors

Publications (2)

Publication Number Publication Date
EP1475086A2 EP1475086A2 (en) 2004-11-10
EP1475086A3 true EP1475086A3 (en) 2006-12-13

Family

ID=27378425

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99945137A Expired - Lifetime EP1107746B1 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors
EP04018454A Withdrawn EP1475086A3 (en) 1998-08-24 1999-08-23 Sibutramine metabolites

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP99945137A Expired - Lifetime EP1107746B1 (en) 1998-08-24 1999-08-23 Methods of using and compositions comprising dopamine reuptake inhibitors

Country Status (20)

Country Link
US (3) US6331571B1 (enExample)
EP (2) EP1107746B1 (enExample)
JP (1) JP2002523366A (enExample)
KR (3) KR20080011354A (enExample)
CN (1) CN100415222C (enExample)
AT (1) ATE279184T1 (enExample)
AU (2) AU772303B2 (enExample)
CA (1) CA2341441C (enExample)
CZ (1) CZ2001677A3 (enExample)
DE (1) DE69921157T2 (enExample)
DK (1) DK1107746T3 (enExample)
ES (1) ES2226435T3 (enExample)
HU (1) HUP0103408A3 (enExample)
ID (1) ID28638A (enExample)
IL (2) IL141531A0 (enExample)
NO (1) NO20010943L (enExample)
NZ (1) NZ510193A (enExample)
PL (1) PL200264B1 (enExample)
PT (1) PT1107746E (enExample)
WO (1) WO2000010551A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
TR200102646T2 (tr) * 1999-03-19 2002-08-21 Knoll Gmbh Yeme bozukluklarının tedavi edilmesi.
KR100948757B1 (ko) * 1999-07-01 2010-03-23 파마시아 앤드 업존 캄파니 엘엘씨 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002036540A2 (en) * 2000-11-02 2002-05-10 Torrent Pharmaceuticals Ltd PROCESS FOR PREPARATION OF β-PHENETHYLAMINE DERIVATIVE
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
ATE409475T1 (de) * 2001-02-20 2008-10-15 Dinan Timothy Gerard Behandlung von fibromyalgie mit pindolol
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
CN1655787A (zh) * 2002-05-30 2005-08-17 神经研究公司 治疗慢性疼痛的三单胺再摄取抑制剂
US20040197397A1 (en) * 2002-08-30 2004-10-07 Watson Pharmaceuticals, Inc. Drug delivery system for treatment of urinary incontinence
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050228052A1 (en) * 2004-01-29 2005-10-13 Barberich Timothy J Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US20050267176A1 (en) * 2004-02-18 2005-12-01 Sepracor Inc. Dopamine-agonist combination therapy for improving sleep quality
US20050266085A1 (en) * 2004-05-28 2005-12-01 Warner Kevin S Gelled emulsion and microemulsion formulations for dermal drug delivery
KR100618176B1 (ko) * 2004-12-02 2006-09-01 휴먼팜 주식회사 시부트라민 주석산염, 이의 제조 방법 및 이를 포함하는약학적 조성물
EP1828096A2 (en) * 2004-12-22 2007-09-05 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Enantioselective synthesis of a sterically hindered amine
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
JP2008526836A (ja) * 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060093564A (ko) * 2005-02-22 2006-08-25 종근당바이오 주식회사 무수 시부트라민 말산염 및 이의 제조 방법
KR100632470B1 (ko) * 2005-02-25 2006-10-12 민연식 결정성 시부트라민 캄실레이트염과 이의 제조방법
WO2006115770A2 (en) * 2005-04-22 2006-11-02 Teva Pharmaceuticals Usa, Inc. Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2006136945A1 (en) * 2005-06-17 2006-12-28 Pfizer Products Inc. METABOLITES OF 1_ [_6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL] -3- [2- (4-METHYL-PIPERAZIN-I-YL) -BE NZYL] -PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS
EP1996194B1 (en) * 2006-03-10 2011-03-09 The Research Foundation Of State University Of New York Homotropanes with central nervous system activity
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
CN101674728A (zh) * 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
MX2009008491A (es) * 2007-02-12 2010-01-20 Dmi Biosciences Inc Tratamiento de disfuncion erectil y eyaculacion prematura copatologicas.
WO2010022236A2 (en) * 2008-08-20 2010-02-25 The University Of Medicine And Dentistry Of New Jersey Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
WO2010126970A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Methods for treating and preventing erectile dysfunction
AU2011291506B2 (en) 2010-08-19 2016-07-28 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN113908295B (zh) * 2021-11-12 2023-07-21 郑州大学第一附属医院 一种阿普唑仑包合物及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3212682A1 (de) * 1981-04-06 1982-10-21 The Boots Co. Ltd., Nottingham Substituierte cyclobutane, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, welche diese verbindungen enthalten
EP0191542A1 (en) * 1985-01-17 1986-08-20 The Boots Company PLC Arylcyclobutylalkyl amines and their use as antidepressive medicines
WO1988006444A1 (en) * 1987-02-28 1988-09-07 The Boots Company Plc Arylcyclobutyl derivatives for treatment of parkinson's disease
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
WO1995021615A1 (en) * 1994-02-11 1995-08-17 Knoll Ag Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
WO1998013034A1 (en) * 1996-09-25 1998-04-02 Knoll Aktiengesellschaft Use of sibutramine analogues to lower lipid levels
WO1999033450A2 (en) * 1997-12-24 1999-07-08 Knoll Aktiengesellschaft Pharmaceutical composition containing sibutramine and orlistat

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3008993A1 (de) 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
JPS5940638A (ja) 1982-08-30 1984-03-06 Fuji Photo Film Co Ltd 直接ポジ用ハロゲン化銀写真乳剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
GB8909209D0 (en) 1989-04-22 1989-06-07 Wyeth John & Brother Ltd Piperazine derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0554172B1 (en) 1992-01-28 1998-04-29 Fujitsu Limited Color surface discharge type plasma display device
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
JPH08500093A (ja) 1992-06-23 1996-01-09 セプラコア インコーポレーテッド 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ATE212860T1 (de) 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9524681D0 (en) 1995-12-02 1996-01-31 Knoll Ag Chemical process
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3212682A1 (de) * 1981-04-06 1982-10-21 The Boots Co. Ltd., Nottingham Substituierte cyclobutane, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, welche diese verbindungen enthalten
EP0191542A1 (en) * 1985-01-17 1986-08-20 The Boots Company PLC Arylcyclobutylalkyl amines and their use as antidepressive medicines
WO1988006444A1 (en) * 1987-02-28 1988-09-07 The Boots Company Plc Arylcyclobutyl derivatives for treatment of parkinson's disease
US4939175A (en) * 1988-03-31 1990-07-03 The Boots Co. Plc Use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
WO1995021615A1 (en) * 1994-02-11 1995-08-17 Knoll Ag Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
WO1998013034A1 (en) * 1996-09-25 1998-04-02 Knoll Aktiengesellschaft Use of sibutramine analogues to lower lipid levels
WO1999033450A2 (en) * 1997-12-24 1999-07-08 Knoll Aktiengesellschaft Pharmaceutical composition containing sibutramine and orlistat

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEETHAM S C ET AL: "(3H)NISOXETINE--A RADIOLIGAND FOR NORADRENALINE REUPTAKE SITES: CORRELATION WITH INHIBITION OF (3H)NORADRENALINE UPTAKE AND EFFECT OF DSP-4 LESIONING AND ANTIDEPRESSANT TREATMENTS", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 35, no. 1, January 1996 (1996-01-01), pages 63 - 70, XP000904764, ISSN: 0028-3908 *
CHEETHAM, S. C. ET AL: "[3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments", NEUROPHARMACOLOGY (1993), 32(8), 737-43, 1993, XP000905163 *
HEAL, D. J. ET AL: "A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents", BR. J. PHARMACOL. (1998), 125(2), 301-308, 1998, XP000905054 *
JEFFERY, JAMES E. ET AL: "Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites", J. CHEM. SOC., PERKIN TRANS. 1 (1996), (21), 2583-2589, 1996, XP000891897 *
LUSCOMBE G P ET AL: "THE CONTRIBUTION OF METABOLITES TO THE RAPID AND POTENT DOWN-REGULATION OF RAT CORTICAL BETA-ADRENOCEPTORS BY THE PUTATIVE ANTIDEPRESSANT SIBUTRAMINE HYDROCHLORIDE", NEUROPHARMACOLOGY,GB,PERGAMON PRESS, OXFORD, vol. 28, no. 2, 1 February 1989 (1989-02-01), pages 129 - 134, XP000613753, ISSN: 0028-3908 *
MAHONY M T: "AN ELECTROPHYSIOLOGICAL AND NEUROPHARMACOLOGICAL STUDY OF SIBUTRAMINE HYDROCHLORIDE AND ITS METABOLITES", DISSERTATION ABSTRACTS INTERNATIONAL, ANN ARBOR, MI, US, vol. 52, no. 11, 1 May 1992 (1992-05-01), pages 5773 - B, XP000613834 *
SCOTT G ET AL: "THE EFFECTS OF BTS 54 505, A METABOLITE OF SIBUTRAMINE, ON MONOAMINE AND EXCITATORY AMINO ACID-EVOKED RESPONSES IN THE RAT DORSOLATERAL GENICULATE NUCLEUS IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 111, no. 1, 1994, pages 97 - 102, XP000904782, ISSN: 0007-1188 *

Also Published As

Publication number Publication date
EP1107746B1 (en) 2004-10-13
CN100415222C (zh) 2008-09-03
ID28638A (id) 2001-06-21
AU5781799A (en) 2000-03-14
US20020188029A1 (en) 2002-12-12
PL200264B1 (pl) 2008-12-31
AU2004200875B2 (en) 2006-10-26
HK1088238A1 (zh) 2006-11-03
DE69921157T2 (de) 2006-02-02
DK1107746T3 (da) 2005-02-14
US20030195261A1 (en) 2003-10-16
CN1735407A (zh) 2006-02-15
HUP0103408A3 (en) 2002-10-28
NO20010943L (no) 2001-04-23
IL141531A0 (en) 2002-05-23
US6331571B1 (en) 2001-12-18
CZ2001677A3 (cs) 2002-02-13
KR20080011354A (ko) 2008-02-01
JP2002523366A (ja) 2002-07-30
PL346843A1 (en) 2002-02-25
AU2004200875A1 (en) 2004-04-01
NZ510193A (en) 2003-09-26
WO2000010551A3 (en) 2000-09-21
HUP0103408A2 (hu) 2002-05-29
CA2341441C (en) 2011-07-19
PT1107746E (pt) 2005-03-31
US7071234B2 (en) 2006-07-04
EP1107746A2 (en) 2001-06-20
AU772303B2 (en) 2004-04-22
DE69921157D1 (de) 2004-11-18
CA2341441A1 (en) 2000-03-02
KR100887008B1 (ko) 2009-03-04
KR20060081725A (ko) 2006-07-13
US6538034B2 (en) 2003-03-25
WO2000010551A2 (en) 2000-03-02
IL141531A (en) 2010-05-31
NO20010943D0 (no) 2001-02-23
ES2226435T3 (es) 2005-03-16
EP1475086A2 (en) 2004-11-10
KR20010085553A (ko) 2001-09-07
ATE279184T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
EP1475086A3 (en) Sibutramine metabolites
JP2003524613A5 (enExample)
CA2352324A1 (en) Derivatives of (-)-venlafaxine and methods of preparing and using the same
PL1678172T3 (pl) Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
JPH02262517A (ja) プテリン誘導体からなる精神疾患症状の治療剤
WO2001034138B1 (en) Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
JP2007517059A5 (enExample)
TWI312679B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
Koller Alcoholism in essential tremor
CA2138998A1 (en) Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
US20040266864A1 (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl-and didesmethyl-metabolites of citalopram
WO2006053082A3 (en) Hydroxybenzoate salts of metanicotine compounds
CA2420177A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
CA2188427A1 (en) Neurotransmitter Release Enhancers
WO2004077938A3 (en) Novel chemical entities and methods for their use in treatment of metabolic disorders
JP2004529936A5 (enExample)
KR100882925B1 (ko) 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
South Wales Antidepressant Drug Trial Group A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness
US11065232B2 (en) Dihydrotetrabenazine for the treatment of anxiety and psychoses
WO2000078765A3 (en) CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS
EP1681063A8 (en) Agent for improving mental disorders
Matsushita et al. Normalization of Padrenoceptor down-regulation by SSRI under chronic stress: A mechanism of action of prophylactic effects of antidepressant drugs
JP2002541192A (ja) Ｓ−ヒドロキシネファゾドン
MX2008012212A (es) Metodos para tratar trastornos cognitivos y otros afines.
Ryder KETAMINE ENANTIOMERS: COMPARATIVE PHARMACOLOGY AND NEUROCHEMICAL EFFECTS.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1107746

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FANG, QUN, K.

Inventor name: SENANAYAKE, CHRISANTHA, H.

Inventor name: JERUSSI, THOMAS, P.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FANG, QUN, K.

Inventor name: SENANAYAKE, CHRISANTHA, H.

Inventor name: JERUSSI, THOMAS, P.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FANG, QUN, K.

Inventor name: SENANAYAKE, CHRISANTHA, H.

Inventor name: JERUSSI, THOMAS, P.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/00 20060101ALI20060810BHEP

Ipc: A61P 25/22 20060101ALI20060810BHEP

Ipc: A61P 25/30 20060101ALI20060810BHEP

Ipc: A61P 25/28 20060101ALI20060810BHEP

Ipc: A61P 25/18 20060101ALI20060810BHEP

Ipc: A61P 25/16 20060101ALI20060810BHEP

Ipc: A61P 25/08 20060101ALI20060810BHEP

Ipc: A61P 25/06 20060101ALI20060810BHEP

Ipc: A61P 25/00 20060101ALI20060810BHEP

Ipc: A61P 15/10 20060101ALI20060810BHEP

Ipc: A61P 3/04 20060101ALI20060810BHEP

Ipc: C07C 47/457 20060101ALI20060810BHEP

Ipc: C07C 251/18 20060101ALI20060810BHEP

Ipc: A61K 31/11 20060101ALI20060810BHEP

Ipc: A61K 31/137 20060101ALI20060810BHEP

Ipc: A61K 31/135 20060101ALI20060810BHEP

Ipc: A61K 31/13 20060101AFI20060810BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20070426

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20110317

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110728